Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 del Fondo para pymes 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se reabrirá el lunes 2 de junio de 2025. Puede consultar más información aquí.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
192
resultados
Última actualización
15/06/2025 [06:53:00]
Resultados 100 a 125 de 192
Resumen de: US2025177560A1
Functionalized nanoparticles for inhibiting or preventing pathogen infections (e.g., viral or bacterial infections, such as coronavirus infections) are described. The nanoparticles comprise a biodegradable polymer core and a lipid coating layer that is functionalized with a pathogen-binding receptor (e.g., an angiotensin-converting enzyme 2 (ACE2) receptor protein) and/or a pathogen-binding antibody or an antigen-binding fragment thereof (e.g., a virus-binding antibody or an antigen-binding fragment thereof). The nanoparticles are further functionalized by a phagocyte-specific ligand, e.g., a phosphatidylserine-containing lipid included in the lipid coating layer, to promote clearance of nanoparticle-bound pathogen. Methods of using the nanoparticles to treat or prevent pathogen infections (e.g., coronavirus infections) are also described.
Resumen de: US2025177556A1
Disclosed herein are methods and compositions related to delivery of pharmaceutical agents by lipid nanoparticles (LNPs) to a cell of a target organ (e.g., an eye, an ear) of a subject.
Resumen de: US2025177303A1
In various embodiments, drug delivery vehicles are provided for co-delivery of a chemotherapeutic agent and a TLR7/8 agonist and/or a lipoxin to a cancer. In certain embodiments the vehicles comprise a silicasome comprising: a porous nanoparticle encapsulated in a lipid bilayer, where the lipid bilayer contains a lipoxin and/or a lipid compatible TLR7/8 agonist disposed in the lipid bilayer, and the chemotherapeutic agent is contained in pores comprising the porous nanoparticle and the chemotherapeutic agent comprises a chemotherapeutic agent that induces immunogenic cell death (ICD); or a liposome comprising a lipid bilayer where the lipid bilayer contains a lipoxin and/or a lipid compatible a TLR7/8 agonist disposed in the lipid bilayer; and the chemotherapeutic agent is inside the liposome and the chemotherapeutic agent comprises a chemotherapeutic agent that induces immunogenic cell death (ICD).
Resumen de: US2025177532A1
The present invention relates to: a temperature-sensitive hydrogel for cancer treatment; a photothermal composition comprising the hydrogel as an active ingredient; and a preparation method for the temperature-sensitive hydrogel for cancer treatment. The temperature-sensitive hydrogel of the present invention includes gold nanostars as active ingredients, and thus can generate heat by light irradiation, thereby exhibiting a photothermal therapy effect. In addition, the hydrogel temperature increases so that the release of nitric oxide (NO) from S-nitrosocysteine can be induced. In addition, the temperature-sensitive hydrogel of the present invention includes S-nitrosocysteine as an active ingredient so that, upon a temperature rise due to a photothermal reaction, the penetration of drugs into a tumor site can be improved by the release of NO, and at the same time, apoptosis of cancer cells can be directly caused; and includes an immunotherapy agent as an active ingredient so that tumor size can be effectively suppressed even with the passage of time. Therefore, as a material that enables complex treatment combined with photothermal therapy and immunotherapy, the temperature-sensitive hydrogel of the present invention having the aforementioned effect can be usefully utilized in the field of medicine for cancer treatment.
Resumen de: US2025177558A1
Compositions, methods, and kits are provided for treating bacterial infections with nanoclusters comprising a metallic core conjugated to a nucleotide. Recalcitrant infections are often difficult to treat because of the presence of persister cells, a subpopulation of bacterial cells that is highly tolerant of traditional antibiotics. Persister cells are dormant, which makes them less susceptible to many antibiotics, which are designed to kill growing cells. Administration of nanoclusters comprising a nucleotide was found to be highly efficacious in eradicating persister cells and for treating infections for a broad range of bacterial species, including Gram-positive and Gram-negative bacteria. Such treatment was effective not only in eradicating planktonic bacteria but also bacteria in biofilms.
Resumen de: US2025179015A1
The present invention provides an ionizable lipid compound having an optimized carbon chain length and an amine head so that the ionizable lipid compound has increased delivery efficiency for an active molecule including, but not limited to, nucleic acids, proteins, small molecule drugs and the like. The present invention further relates to a lipid nanoparticle (LNP) comprising the ionizable lipid compound and the active molecule, and a pharmaceutical composition comprising the lipid nanoparticle.
Resumen de: JP2023120371A
To provide a composition including an improved lipid-based nanoparticle, achieving reduction in the delivery of API to an in vivo undesirable tissue and also reduction in toxicity.SOLUTION: A composition comprises a lipid-based nanoparticle, wherein the nanoparticle is enclosed by a bipolar lipid membrane, which comprises cholesterol, dicetyl phosphate, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and (biotin DHPE), wherein the membrane further comprises at least one agent selected from the group consisting of stearoyl lysophosphatidylcholine and m-cresol, wherein the membrane comprises cholesterol, dicetyl phosphate, DSPC, stearoyl lysophosphatidylcholine, m-cresol, and biotin DHPE in a certain ratio such as 9.4:18.1:56.8:14.1:0.0:1.5, wherein the biotin-DHPE extends outward from the nanoparticle, and wherein the size of the nanoparticle ranges from about 10 nm to about 150 nm.SELECTED DRAWING: None
Resumen de: US2025179034A1
One or more ionizable lipid(s) and lipid nanoparticles comprising same are provided. Pharmaceutical compositions comprising the lipid nanoparticles encapsulating an active agent are also provided.
Resumen de: US2025177479A1
An embodiment relates to a depsipeptide-based building block for inhibiting protein-protein interactions, a nanostructure including the same, and a use thereof, wherein the depsipeptide-based building block may remain in the body and cells for a long time when administered in vivo and be delivered to a target tissue with high efficiency, and a peptide for inhibiting protein-protein interactions may be gradually released over a long time to obtain a high effect.
Resumen de: US2025177461A1
A particle containing a virus encapsulated in an amorphous silica shell is described, wherein the amorphous silica shell is directly deposited about the surface of the virus. Also described is a method of producing a virus encapsulated in an amorphous silica shell, the method comprising enriching or purifying a virus; suspending the virus in buffer, hydrolysing a silica precursor directly contacting the hydrolysed silica precursor with the surface of the virus in buffer and encapsulating the virus in an amorphous silica shell.
Resumen de: US2025177305A1
A method of producing a lipid-encapsulated RNA nanoparticle, comprising the steps a) flowing an aqueous solution comprising an RNA through a 1st tube having an inner diameter (ID) of between about 0.1″ and 0.132″; b) flowing an ethanol solution comprising lipids through a 2nd tube having an ID of between about 0.005″ and 0.02″ at one third the flow rate of the aqueous solution through the 1st tube, wherein the lipids comprise a cationic lipid; and c) mixing the ethanol solution with the aqueous solution by flowing the ethanol solution and the aqueous solution into a mixing module consisting of the 2nd tube perpendicularly joined to the 1st tube; wherein the mixing produces an output solution flowing in the 1st tube comprising a turbulent flow of the RNA and the lipids in between about 10% to 75% ethanol v/v, and wherein the lipid-encapsulated RNA nanoparticles have a bilayer structure.
Resumen de: US2025177576A1
The present invention relates to new compounds and uses of these compounds for determining oxygen levels in a sample medium.The compounds of the invention are compounds according to Formula (I):wherein,M is a transition metal;R1, R2, R3, R4, R5, R6, R7 and R8 are each independently selected from the group consisting of hydrogen, halogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C14 aryl, optionally substituted heteroaryl and —N(Y)2;n is 0 to 4;Y is a C1-C6 alkyl, or a C1-C6 haloalkyl;X is C or N; andZ is independently selected from the list consisting of S, Se, and Te.
Resumen de: US2025177577A1
The present disclosure features imaging media including a contrast agent encapsulated within a biodegradable nanoparticle matrix. The particles are sized such that they avoid excretion via urinary excretion (e.g., at least 5 nm in diameter) during an imaging procedure or an image-guided procedure. Instead, the particles are predominantly removed from circulation by the reticuloendothelial system of the liver. This results in a buildup of contrast agent in the liver, allowing for a highly specific imaging modality for liver imaging. Further, the bulk of the imaging media is excreted into the bowel, reducing in-vivo toxicity of the imaging media. Finally, because of their size, the nanoparticles of the imaging media have a higher circulation half-life.
Resumen de: US2025177561A1
The present disclosure relates to ophthalmic compositions containing solid complexes of active pharmaceutical ingredient and cyclodextrin, to their method of preparation and their uses. The compositions can include an active agent drug/cyclodextrin complex substantially dissolved in an aqueous eye drop vehicle. The ophthalmic composition is generally in the form of a microsuspension including an active agent complex having a diameter of less than about 100 μm.
Resumen de: US2025177562A1
Provided are aerosolized pharmaceutical compositions including comprising aerosol particles, the aerosol particles comprising lipid nanoparticles (LNPs). Also provided herein are methods of administering the aerosolized pharmaceutical compositions described herein.
Resumen de: US2025177559A1
There are provided herein, inter alia, complexes, compositions and methods for the delivery of nucleic acid into a cell in vivo. The complexes, compositions and methods may facilitate complexation, protection, delivery and release of oligonucleotides and polyanionic cargos into target cells, tissues, and organs both in vitro and in vivo.
Resumen de: US2025177483A1
The present invention relates to compositions comprising transmembrane stem cell factor (tmSCF) lipid nanocarriers and methods of use thereof.
Resumen de: US2025177345A1
The present invention relates to platinum (IV) prodrug lipid-based amphiphiles and compositions thereof. In particular, it relates to cisplatin, oxaliplatin and carboplatin prodrugs with the capacity to make stable liquid crystalline nanoparticles and crystalline nanoparticles, and uses thereof to treat cancer in animals, including human.
Resumen de: US2025177318A1
Provided are functional segregated telodendrimers having, for example, two or three functional segments. The telodendrimers can aggregate to form nanocarriers. The telodendrimers can have one or more tetracycline drugs (such as CMT-3) physically bound thereto that release under physiological conditions. Such nanocarriers with loaded CMT-3 disperse stably in aqueous solution and may be used in treating inflammatory disease through local or systemic administration. Also provided are methods of treating acute respiratory distress syndrome (ARDS) and/or CARDS in a subject in need thereof, including: administering a therapeutically effective amount of CMT-3 and one or more nonantimicrobial host-modulators directly to the lungs of the patient. In embodiments, CMT-3 is administered to the lungs in an aerosolized formulation. In embodiments, subsequent to CMT-3 administration, one or more non-antimicrobial host-modulators directly to the lungs of the patient.
Resumen de: US2025177319A1
A bacteria-responsive color-changing, core-shell nanofiber, comprising polyurethane (PU), a hemicyanine-based chromogenic probe localized in the core-shell nanofiber near the surface of the shell, polyvinylpyrrolidone (PVP) dopant in the shell, the hemicyanine-based chromogenic probe further comprising a labile ester linkage that is enzymatically cleavable by bacterial lipase released from clinically relevant strains of bacteria including Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA).
Resumen de: US2025177317A1
A lipid nanoparticle based composition and method for making the same is provided. The lipid nanoparticle based composition includes an in-vitro transcribed (IVT) mRNA molecule containing (a) a 5′ cap structure, (b) a coding region encoding an antigen polypeptide, (c) an immunostimulatory RNA sequence that activates RIG-I, (d) a poly (A) tail, and (e) a TLR antagonist based on a phospholipid.
Resumen de: US2025177437A1
Some embodiments include methods of treating, inhibiting, or ameliorating ischemic stroke or a symptom thereof in a subject. Some embodiments include oxygenated fluid for use in treating, inhibiting, or ameliorating ischemic stroke. The oxygenated fluid may comprise charge-stabilized oxygen-containing nanostructures.
Resumen de: US2025177432A1
This disclosure provides compositions and methods for treating cancers. The compositions include mRNA molecules encoding proteins useful for treating the cancers, such as IL-12, an OX40 agonist, and optionally along with FADD, MLKL or MLKL-4HB. The mRNA can include 5′UTR and 3′UTR sequences and 5′cap structures that improve the stability and/or therapeutic effects of these mRNA molecules.
Resumen de: US2025177301A1
A multi-layer (multi-lamellar) coated nanoparticle is provided wherein the nanoparticle comprises a first coat comprising a positively charged polymer or a positively charged lipd bilayer and a second coat comprising an anionic bilayer and optionally one or more distinct cargo molecules, one or more distinct targeting moieties, or any combination thereof, as well as methods of making and using the nanoparticle.
Nº publicación: AU2023385865A1 05/06/2025
Solicitante:
MORRISON ERIC
MORRISON, Eric
Resumen de: AU2023385865A1
Disclosed herein are dense nanolipid fluid (DNLF) dispersions comprising desirable characteristics for incorporating bioactive agents such as peptides into lipid phase of the dispersion for biodelivery of the agents for their typical purpose. Continuous methods for preparing the DNLF dispersions are also disclosed herein to include formation of a crude mill base and passing the base through a twin screw extruder. Dispersions disclosed herein can express a particle size of less than 150 nm under stable storage conditions, while forming lamellar structures after exposure to heat and/or evaporation of the aqueous components of the dispersion.
BOPI
Sede Electrónica
